Recurrence: all 3,523 studies

Page 18 of 36. Open to participants first (870), then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/OverexpressionWithdrawnNCT05512182Phase 2
• Percutaneous Nephroscopic Treatment of Parapelvic CystsStatus unknownNCT05504512
• Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple MyelomaNo longer availableNCT05503550
• A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell LymphomaStatus unknownNCT05495100Phase 2
• Effects of Recurrent Application of Liquid-PRF on Hard and Soft TissuesCompletedNCT05492357Not applicable
• Spine Registry University Hospital of Cologne- Department of OrthopedicsCompletedNCT05486494
• Molecular Subtyping for Prognosis Evaluation in Resected Pancreatic AdenocarcinomaCompletedNCT05483257
• Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction CancerActive, not recruitingNCT05476796Phase 2
• Risk of Breakthrough Symptoms With Long-Acting Injectable MedicationsCompletedNCT05473741
• A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)CompletedNCT05470140Phase 1
• Tazemetostat for the Treatment of Relapsed/Refractory Follicular LymphomaCompletedNCT05467943Phase 2
• Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma PatientsApproved for marketingNCT05463939
• Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple MyelomaNo longer availableNCT05462639
• A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)Active, not recruitingNCT05460533Phase 2
• Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedNCT05459571Phase 2
• Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AMLCompletedNCT05456048
• STereotactic sAlvage Radiotherapy for Macroscopic Prostate Bed Recurrence After prostatectomy-a Prospective Observational StudyStatus unknownNCT05455736
• Niraparib Efficacy in Patient With Unresectable MesotheliomaCompletedNCT05455424Phase 2
• A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular LymphomaActive, not recruitingNCT05451810Phase 2
• Sensory Integration Disorders in Patients With MS Including Disease Advancement and Relapses in the Last YearCompletedNCT05449574
• CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALLCompletedNCT05440409
• Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid TumorsTerminatedNCT05429502Phase 1
• In Vitro Immunomodulation in Membranous Nephropathy RelapsesCompletedNCT05428605Not applicable
• Clinical Study of TQB2618 Injection in Combination With Demethylation Drugs in Patients With Recurrent/Refractory Acute Myeloid Leukemia, Myelodysplastic SyndromesStatus unknownNCT05426798Phase 1
• Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid TumorsCompletedNCT05415475Phase 1
• Contribution of Lower Limb Venous Colour Doppler Ultrasound in the Diagnosis of Pulmonary Embolism RecurrenceCompletedNCT05413317
• Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous MastitisCompletedNCT05409586
• Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMMWithdrawnNCT05408026Phase 1/2
• Clinical Outcomes of Persistent Atrial Fibrillation Ablation Using Ablation Index-guided Radiofrequency Catheter Ablation in Patients With Continuous MonitoringWithdrawnNCT05406310
• Mobile Chat Messaging for Smoking Relapse PreventionCompletedNCT05370352Not applicable
• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS ParticipantsWithdrawnNCT05367401Phase 1/2
• A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHLWithdrawnNCT05365100Phase 1/2
• Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial CarcinomaCompletedNCT05364905
• Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaActive, not recruitingNCT05363800Phase 1
• Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLLTerminatedNCT05360238Phase 1/2
• IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint InhibitorActive, not recruitingNCT05359445Phase 1
• Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsTerminatedNCT05357898Phase 1/2
• A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid LeukemiaTerminatedNCT05345938Phase 1/2
• Unroofing Curettage for Pilonidal DiseaseCompletedNCT05339828
• Endoscopic Resection of Papillary Adenomas; a Novel Treatment Algorithm to Prevent Recurrence - a Pilot-study (ERASE-pilot)Status unknownNCT05339607Not applicable
• Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT05338892
• A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric CancerCompletedNCT05334719
• Recurrence Markers, Cognitive Burden and Neurobiological Homeostasis in Late-Life DepressionActive, not recruitingNCT05331599
• GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
• Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)TerminatedNCT05329545Phase 3
• A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)CompletedNCT05324436
• Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ LymphomaStatus unknownNCT05320081Phase 2
• Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
• Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian PatientsCompletedNCT05314673Phase 4
• Comparison of Hernia Sac Ligation Versus InvaginationCompletedNCT05308251Not applicable
• Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma PatientsActive, not recruitingNCT05300282Phase 1/2
• Ancillary Study of the ULTREC ProjectCompletedNCT05300139
• KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05294172Phase 3
• Ocrelizumab Discontinuation in Relapsing Multiple SclerosisActive, not recruitingNCT05285891Phase 4
• A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin LymphomaActive, not recruitingNCT05283720Phase 2
• A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic MalignanciesWithdrawnNCT05279859Phase 1/2
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
• A Study to Investigate LYL797 in Adults With Solid TumorsTerminatedNCT05274451Phase 1
• Independent Risk Factors Analysis and Model Construction For Recurrence After Radiofrequency/Microwave Ablation of Colorectal Cancer With Liver Metastases: a Retrospective, Multicenter TrialStatus unknownNCT05268549
• Adenocarcinoma of the Uterine Cervix and HPVCompletedNCT05267834
• Ligation of Intersphincteric Fistula Tract Versus Rectal Advancement Flap in the Treatment of Complex Anal FistulaStatus unknownNCT05263661Phase 3
• Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaCompletedNCT05263583Phase 2
• Risk Factors for Recurrent Intussusception Successful Reduction in Pediatric PatientsCompletedNCT05259670
• RElapse After Allograft: Link Between LoCus of Control and QualiTy of LifeTerminatedNCT05258929
• NK Cell Therapy for AMLTerminatedNCT05256277Phase 1
• Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)Active, not recruitingNCT05253118Phase 2
• Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT.CompletedNCT05250765Not applicable
• NKG2D CAR-NK Cell Therapy in Patients With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT05247957Not applicable
• Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)No longer availableNCT05238311
• A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Phase 3
• Primaquine Double Dose for Radical Cure of Plasmodium Vivax in ColombiaWithdrawnNCT05232227Phase 2/3
• Study of ORIC-533 in Relapsed or Refractory Multiple MyelomaCompletedNCT05227144Phase 1
• To Evaluate the Safety and Tolerability of Human CD19-CD22 Targeted T Cells Injection for Subjects With R/R B-ALL.Status unknownNCT05223686Phase 1
• Lymph Node Ratio as a Predictor for Outcome in Rectal CancerStatus unknownNCT05221684
• Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )Active, not recruitingNCT05221229
• Evaluation of Relapse Presence in Multiple SclerosisCompletedNCT05218317
• A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word ConditionsCompletedNCT05217914
• A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class ExposureCompletedNCT05217082
• Conservative Treatment of Ingrown ToenailCompletedNCT05214586Not applicable
• CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ LymphomaStatus unknownNCT05212584Phase 1
• Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of EpcoritamabActive, not recruitingNCT05206357Phase 1
• Deep Learning Model for the Prediction of Post-LT HCC RecurrenceCompletedNCT05200195
• A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AMLActive, not recruitingNCT05199051Phase 2
• CAV Regimen Bridging to HSCT for R/R ALCompletedNCT05190549Phase 2
• Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)Active, not recruitingNCT05182385Phase 1/2
• Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple MyelomaWithdrawnNCT05170789Phase 2
• Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)Approved for marketingNCT05164250
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active, not recruitingNCT05156281Phase 3
• Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)Status unknownNCT05155839Phase 1
• A Study of Alpelisib and Fulvestrant to Treat Endometrial CancerActive, not recruitingNCT05154487Phase 2
• Venetoclax Based Regimen for R/R T-ALLCompletedNCT05149378Phase 2
• Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular CarcinomaActive, not recruitingNCT05148572
• Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingNCT05147220Phase 3
• Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled TrialStatus unknownNCT05146635Not applicable
• A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)CompletedNCT05144841Phase 2
• PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
• Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRDStatus unknownNCT05137860Phase 4
• Effects of Recurrent PE on Women and OffspringStatus unknownNCT05134285
• An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)No longer availableNCT05131438
• A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Phase 2

← Recurrence overview